FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 233 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... July 2, 2020 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 How to Spot Suspicious Herb and Supplement Claims During Cancer June 29, 2021 Load more HOT NEWS CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative... Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma...
